Opinion|Videos|July 17, 2024
Final Thoughts on CSPC
Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do you foresee the early treatment paradigm for CSPC evolving in the coming years?
- Are there other novel agents you're excited about in development?
- How will their availability impact treatment sequencing strategies?
Advertisement
Related to this article
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
2
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5